Senolytics
About Senolytics
Senolytics are a class of therapies designed to selectively eliminate senescent cells to mitigate aging related diseases and improve healthspan. The field has activity across biotech startups and research collaborations, with several programs advancing in preclinical and early clinical stages and interest from pharma in licensing and development partnerships.
Trend Decomposition
Trigger: Increasing scientific evidence that senescent cells contribute to aging and chronic disease, fueling investment in therapies that selectively clear these cells.
Behavior change: Researchers and companies are prioritizing senolytic targets in drug development pipelines and pursuing combination therapies aimed at aging biology.
Enabler: Advances in senescent cell biomarkers, high throughput screening, and geroscience understanding enable selective targeting and safety profiling.
Constraint removed: Feasibility of safely eliminating senescent cells in humans without compromising tissue repair or immune function.
PESTLE Analysis
Political: Public funding and policy support for aging research influence funding patterns and clinical trial incentives.
Economic: Capital inflows from biotech investors and potential near term partnerships with large pharma drive commercialization trajectories.
Social: Aging populations increase demand for therapies addressing age related diseases and healthspan extension.
Technological: Biomarker assays and senescence associated secretory phenotype (SASP) profiling improve patient selection and trial endpoints.
Legal: Regulatory frameworks for anti aging therapies shape trial design and approval pathways.
Environmental: Sustainable manufacturing and supply chain considerations for biologics and small molecules used as senolytics.
Jobs to be done framework
What problem does this trend help solve?
Reduce burden of aging related diseases by clearing senescent cells to improve healthspan.What workaround existed before?
Treatments targeted at individual diseases without addressing underlying senescence biology; lifestyle interventions offered limited systemic impact.What outcome matters most?
Certainty and speed in demonstrating meaningful healthspan benefits with acceptable safety.Consumer Trend canvas
Basic Need: Longevity and quality of life through healthier aging.
Drivers of Change: Aging demographics, increasing biotech funding, and improved understanding of senescence biology.
Emerging Consumer Needs: Clear evidence of benefit, predictable safety, and accessible therapies.
New Consumer Expectations: Therapeutics that meaningfully extend healthy years with manageable risk.
Inspirations / Signals: Positive clinical readouts in senolytic programs and interest from major biopharma.
Innovations Emerging: Targeted senolytics, senomorphics, and biomarker guided trial designs.
Companies to watch
- Unity Biotechnology - Biotech company focused on senolytic therapies targeting aging related diseases.
- Oisín Biotechnologies - Biotech firm developing systemic senolytics using in vivo approaches.
- Cleara Biotech - Company pursuing senolytic strategies and related aging therapies.
- Life Biosciences - Investment and development entity funding senescence and aging related programs, including senolytics.